Study of two drugs for relapsed peripheral T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests two new drugs (SHR-0302 and SHR-2554) for people with a type of lymphoma (peripheral T-cell lymphoma) that has come back or not responded to prior treatment. The goal is to see if the combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have been diagnosed with peripheral T-cell lymphoma (a type of cancer that starts in certain white blood cells).
- Your lymphoma came back after at least one treatment, or didn't respond to it.
- You must have at least one tumor that can be measured on a scan or exam.
- You must be able to take care of yourself (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three medicines (anti-PD-1, lenalidomide, and azacitidine) for adults with relapsed or refractory peripheral T-cell lymphoma (PTCL) that is measurable or growing. It aims to shrink lymphoma and improve control of the disease when standard treatments haven’t worked or have stopped working.
This trial tests a new tablet, XNW5004, for people with peripheral T-cell lymphoma that has come back or hasn't responded to at least two prior treatments. The goal is to see if it can help shrink tumors or stop the cancer from growing.
This study tests a new oral tablet called XNW5004 for people with peripheral T-cell lymphoma (a type of blood cancer) that has come back or not responded to prior treatments. The goal is to see if this drug can help shrink tumors or slow the disease.
This trial tests a combination of three drugs (bendamustine, chidamide, and lenalidomide) for patients with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to see if this new combination can help when standard treatments have failed.
This early-phase study tests a new treatment called STR-P004 for people with certain aggressive B-cell lymphomas that have not responded to or returned after two or more prior treatments. The goal is to see if it is safe and effective.
This trial tests a new drug, SHR2554, for people with follicular lymphoma that has returned or not responded to prior treatments. It aims to see if the drug can shrink tumors and slow the cancer's growth.
Hear when a new Relapsed/Refractory Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.